 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...5455565758596061626364...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Cigarette Smoke Containing Acrolein Upregulates EGFR Signaling Contributing to Oral Tumorigenesis In Vitro and In Vivo. (Pubmed Central) - Jul 28, 2021
Inhibiting EGFR pathway using an anti-EGFR antibody, cetuximab, inhibits tumor growth...Taken together, our results indicate that acrolein is important in tumorigenic transformation through amplification of EGFR and activating the downstream signaling pathway, contributing to oral carcinogenesis. This is the first study to provide molecular evidence showing that CS containing acrolein contributes to EGFR amplification in OSCC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. (Pubmed Central) - Jul 28, 2021
Drugs such as pembrolizumab and nivolumab have demonstrated success in recent clinical trials and have been approved for the treatment of advanced disease. Given the positive results of both EGFR targeted agents and immune checkpoint inhibitors, ongoing trials are studying their synergistic effects.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Review, Journal: Precision medicine: Uses and challenges. (Pubmed Central) - Jul 27, 2021
Numerous challenges still exist to the future of precision medicine such as cost involved, ethics, security of the Big data, merger of various platforms to integrate data and also availability of trained manpower to manage the data and algorithms. This new age medicine is a big step forward for mankind and hopefully it will bring more benefits for both patients and the caregivers in the near future.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: NMR Profiling of Ononis diffusa Identifies Cytotoxic Compounds against Cetuximab-Resistant Colon Cancer Cell Lines. (Pubmed Central) - Jul 24, 2021
The fractions obtained were again tested for their biological activity and their metabolite content was determined by 1D and 2D NMR analysis. The study led to the identification of a fraction enriched in oxylipins that showed a 92% growth inhibition of the HT-29 cell line at a concentration of 50 µg/mL.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Rapid drug desensitization (RDD) to anticancer drugs: A 4-year monocentric experience () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2964;
Only 2.6% of RDDs elicited BRTs, which were in most cases (61.9%) mild or moderate. Moreover, no cases of anaphylaxis or death during the RDDs were recorded.
- depatuxizumab (ABT-806) / AbbVie, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2703;
Pts with EGFR-amplified EGC derive clinical benefit from EGFR inhibition, which is most pronounced in the absence of intrinsic resistance mechanisms. An upcoming trial of amivantamab in EGFR and/or MET amplified EGC is planned.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2649;
P1/2
Background: First- and third-generation epidermal growth factor receptor (EGFR) inhibitors such as gefitinib and osimertinib, respectively, have improved survival outcomes for patients with advanced EGFR-mutant NSCLC...Synergistic efficacy of BBT-176 with Cetuximab was also observed in animal studies...When RP2D is determined in Part 1, then Part 2 will be initiated to evaluate efficacy in molecularly selected target populations. Objective response rate, duration of response and progression-free survival will be measured in addition to safety and tolerability of BBT-176 at RP2D (NCT04820023).
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Real-world treatment patterns and outcomes of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) in the US () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2366;
The prognosis of patients with mCSCC was generally poor. Most CSCC related healthcare costs were due to OP costs.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2333;
P1b/2
The planned enrollment is 78 patients. Ltd., funded by Nektar Therapeutics, San Francisco, CA.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2238;
The response to CPI is an independent positive predictor for long-term survival. Taxan-based treatment appears to be the most promising strategy after failure of CPI and platinum.
- simlukafusp alfa (RG7461) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2222;
P1a/1b
The safety profile of SIM in combination with CET was consistent with the safety of each component, and did not lead to unexpected overlapping toxicities. Despite exceptional responders with prior CPI, overall low anti-tumor activity does not warrant further clinical exploration in HNSCC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Clinical predictors for survival with the addition of chemotherapy in patients with recurrent-metastatic squamous cell carcinoma of the head and neck after progression on immune checkpoint inhibitors () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2204;
A group of pts with R/M HNSCC will benefit from SC after progression on ICI. ICI treatment interval, P-16, hemoglobin, albumin, and PS should be studied as potential markers for treatment selection in this population.
- barecetamab (ISU104) / ISU Abxis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2203;
P1
Encouraging clinical efficacies and potential biomarkers were demonstrated from combination therapy. A phase II study of ISU104 (Q3W, 20 mg/kg/day) in combination with CET (Q1W) is planned to further strengthen the clinical utility of ISU104.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1873;
P3
Efficacy endpoints were compared using two-sided stratified log-rank test. Superiority of Arm A to Arm B in terms of mPFS can be concluded if two-sided p value <0.05.
- MEN1611 / Menarini, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] MEN1611 in combination with cetuximab: Targeting PIK3CA mutations in RAS-wild-type patient-derived colorectal cancer xenografts () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1851;
P1/2
In conclusion, in the selected genetic setting, the combination of MEN1611 with cetuximab displayed higher activity compared to single agents showing a synergistic effect in cetuximab-resistant PDX models. These data support the ongoing C-Precise phase Ib/II study investigating anti-tumor activity and safety of MEN1611 in combination with cetuximab in PIK3CAmut/N-K-RASwt/BRAFwt mCRC patients (NCT04495621).
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Elunate (fruquintinib) / Hutchmed
[VIRTUAL] A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1848;
Cetuximab combined with fruquintinib showed acceptable anti-tumor activity in CRC with resistance to at least two prior regimens. No unexpected toxicities were observed.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1841;
TA-high subtype was associated with better OS in RAS wt mCRC pts treated with Cmab/Pmab suggesting TA-ness classification may be useful for antiEGFR treatment selection. Further analyses from prospective clinical trials are necessary to validate our .
- fosifloxuridine nafalbenamide (NUC-3373) / NuCana, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1838;
P1/2
NUC-3373 ± LV was well tolerated and has a favourable PK profile that is not affected by LV. Encouraging efficacy signals have been observed in heavily pre-treated CRC patients.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
[VIRTUAL] A study of vemurafenib and cetuximab in combination with FOLFIRI for patients with BRAF V600E-mutated advanced colorectal cancer (NCT03727763): Preliminary results () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1804;
P2
A combination of vemurafenib, cetuximab and FOLFIRI was generally well-tolerated and the preliminary result indicated considerably increased response rate for advanced colorectal cancer patients with BRAF V600E mutation. The enrollment for the trial is still under way.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1803;
The oncological outcomes observed here are very close to those reported in the BEACON pivotal trial. The use of an anti-BRAF and an anti-EGFR combination should not be ruled out in this population with limited therapeutic options and poor prognosis.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1792;
P2
The use of an anti-BRAF and an anti-EGFR combination should not be ruled out in this population with limited therapeutic options and poor prognosis. Although the cetuximab maintenance arm did not meet the primary objective, a clinically meaningful difference in PFS in favor of cetuximab maintenance was found in RAS/BRAF wt mCRC patients.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Cetuximab could be administered once every two weeks instead of once weekly () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1788;
P2
Our model allowed quantifying EGFR kinetics over time, which was associated to PFS. Our simulations suggested that a 500mg/m2 Q2W regimen could be used instead of 250mg/m2 QW in some patients.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1778;
These subgroup analyses support the consistent findings observed for OS in patients with RAS wt mCRC with left- and right-sided PTLs treated with first-line q2w vs q1w CET in combination with chemotherapy. No significant difference was shown in terms of frequency of any SAEs.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials (Channel 4) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1344;
CC patients with diabetes type 2 had a significantly worse survival as well as shorter TTR. Furthermore, our data suggest that metformin may attenuate the detrimental effect of diabetes on CC patient outcomes.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial (Channel 4) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1338;
P2
Furthermore, our data suggest that metformin may attenuate the detrimental effect of diabetes on CC patient outcomes. This exploratory analysis suggests that patients with any tumour mutation in MAPK pathway genes are not good candidates for maintenance treatment with cetuximab or treatment interruption after first-line FOLFIRI-cetuximab.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial (Channel 1) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1146;
P3
In cisplatin-Unfit pts, a favorable effect of adding avelumab to cetuximab was seen on PFS, local-regional control, distant metastases, but the primary endpoint on PFS was not met. In cisplatin-Fit pts, the futility boundary for efficacy was crossed, favoring SOC cisplatin.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Astonishing response to Cetuximab in metastatic nasopharyn- geal carcinoma: a case report. (Pubmed Central) - Jul 22, 2021
We report a case of 58 years old patient with metastatic nasopharyngeal carcinoma with an astonishing response to Cetuximab. At the time of writing, the patient is still in treatment with Cetuximab with excellent disease control.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Conversion to Complete Resection with mFOLFOX6 with Bevacizumab or Cetuximab Based on K-RAS Status for Unresectable Colorectal Liver Metastasis (BECK study): Long-Term Results of Survival. (Pubmed Central) - Jul 21, 2021
Conversion hepatectomy achieved a similar long-term survival to the results of previous studies in initially resectable patients, although many of them experienced several post-hepatectomy recurrences. Left-sided primary was found to be the predictor for conversion hepatectomy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, P2 data, Journal, Combination therapy: BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. (Pubmed Central) - Jul 21, 2021
The primary endpoint is the confirmed objective response rate in the primary analysis cohort. UMIN000031857 and 000031860.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Retrospective data, Journal: First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. (Pubmed Central) - Jul 21, 2021
Conventional pathological classification (e.g. MA/MC) should be considered when tailoring the individualized optimal treatment for mCRC. Bevacizumab plus chemotherapy as first-line therapy may be the optimal option for patients with MA/MC.
- || SNK01 / NKMAX
Enrollment open, Combination therapy, Metastases: SNK_ASTER: A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (clinicaltrials.gov) - Jul 20, 2021
P1/2, N=24, Recruiting, Sponsor: NKMAX Co., Ltd.
Bevacizumab plus chemotherapy as first-line therapy may be the optimal option for patients with MA/MC. Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Real-world evidence, Real-world, Metastases: Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data. (clinicaltrials.gov) - Jul 19, 2021
P=N/A, N=500, Recruiting, Sponsor: Grupo Espa
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Monotherapy: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor (clinicaltrials.gov) - Jul 18, 2021
P3, N=81, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Clinical: JCI Insight - First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients @JCI_insight https://t.co/SfyyAJOgw0 (Twitter) - Jul 17, 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 16, 2021
P2, N=128, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. (Pubmed Central) - Jul 16, 2021
Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2021 PTS may impact the response to nivolumab in HNSCC patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Cetuximab Exhibits Sex Differences in Lymphatic Exposure after Intravenous Administration in Rats in the Absence of Differences in Plasma Exposure. (Pubmed Central) - Jul 16, 2021
These data suggested that mAbs more efficiently access lymph in females, but this does not affect plasma pharmacokinetics or biodistribution. Further, the data suggest that sex differences observed in humans could be a function of antigen density.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. (Pubmed Central) - Jul 16, 2021
P2
Cetuximab plus paclitaxel/carboplatin did not improve PFS, OS and RR in metastatic CUP compared to paclitaxel/carboplatin alone. Addition of cetuximab resulted in additional skin toxicity.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Immunogenic cell death, IO biomarker: Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment. (Pubmed Central) - Jul 16, 2021
Although cetuximab (CTX) is a chimeric epidermal growth factor receptor (EGFR) antibody, the antitumor efficacy of CTX has a negligible effect in patients with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutated pancreatic adenocarcinoma...Furthermore, a large number of CD4 , CD8 T cells and mature DCs and natural killer cells are infiltrated in CMPC with laser-treated tumor tissues and tumor-draining lymph nodes, revealing both innate and adaptive cellular immune stimulation. This synergistic effect with CMPC and laser treatment provides an effective approach for pancreatic cancer immunotherapy attributed to both CTX and PDT.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Adverse events: Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection. (Pubmed Central) - Jul 15, 2021
Its positive and negative predictive values were 100%. Specific IgE detection of cetuximab or alpha-gal can accurately predict cetuximab-induced anaphylaxis prior to first administration.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma. (Pubmed Central) - Jul 15, 2021
Specific IgE detection of cetuximab or alpha-gal can accurately predict cetuximab-induced anaphylaxis prior to first administration. PTEN activation may enhance the antitumor effect of PTX + cMab.
- ||| Krazati (adagrasib) / BMS
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (clinicaltrials.gov) - Jul 14, 2021
P1/2, N=565, Recruiting, Sponsor: Mirati Therapeutics Inc.
PTEN activation may enhance the antitumor effect of PTX + cMab. N=391 --> 565 | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 14, 2021
P2, N=70, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
N=391 --> 565 | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Improved therapeutic antibody delivery to xenograft tumors using cavitation nucleated by gas-entrapping nanoparticles. (Pubmed Central) - Jul 14, 2021
Aims: Testing ultrasound-mediated cavitation for enhanced delivery of the therapeutic antibody cetuximab to tumors in a mouse model...When nucleated by Sonovue, a 2.1-fold increase (95% CI 1.3- to 3.4-fold) was measured, whereas SonoTran Particles gave a 3.6-fold increase (95% CI 2.3- to 5.8-fold). Ultrasound-mediated cavitation, especially when nucleated by nanoscale gas-entrapping particles, can noninvasively increase site-specific delivery of therapeutic antibodies to solid tumors.
- | Trial completion date, Metastases: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Jul 14, 2021
P1, N=80, Not yet recruiting, Sponsor: Hoffmann-La Roche
Ultrasound-mediated cavitation, especially when nucleated by nanoscale gas-entrapping particles, can noninvasively increase site-specific delivery of therapeutic antibodies to solid tumors. Trial completion date: Jul 2023 --> Dec 2024
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Identification and prognostic analysis of the cetuximab resistance-related gene REV1 in RAS wild-type metastatic colorectal cancer. (Pubmed Central) - Jul 13, 2021
Data from the Genomics of Drug Sensitivity in Cancer and the Gene Expression Omnibus databases suggested low REV1 mRNA levels might be related to the poor response of CRC cells and reduced cetuximab efficacy among mCRC patients. In conclusion, REV1 expression levels and the REV1: c.2108G > A mutation may be related to cetuximab resistance in RAS wild-type mCRC.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: In fact, it was the allergic reaction to cetuximab in patients that led Dr. Thomas Platts-Mills of @UVA to the discovery of IgE against alpha-gal and eventually linking it back to Lone Star ticks. (9/n) https://t.co/wPVYglWlx8 (Twitter) - Jul 10, 2021
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical: Alpha gal is also present in other mammalian-based products including medications, cosmetics, vaccines, gelatin, and milk products 🍦. Even biologics like cetuximab (a chimeric antibody containing alpha-gal within mouse portion) can induce reaction. (8/n) https://t.co/zjD7oI6FyS (Twitter) - Jul 10, 2021
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
Looking for trials or ideas for progression post-FOLFOx and Vemurafenib, Cetuximab-Irinotecan (pre-BEACON pt!) for BRAF V600E #CRCSM. Pt willing to travel. CC: @manjuggm @dralanburguete @pashtoonkasi @GIcancerDoc @CathyEngMD @DrR_DUNNE @gabe_a_brooks (Twitter) - Jul 10, 2021
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Jul 9, 2021
P1/2, N=383, Active, not recruiting, Sponsor: MedImmune LLC
In conclusion, REV1 expression levels and the REV1: c.2108G > A mutation may be related to cetuximab resistance in RAS wild-type mCRC. Trial completion date: Apr 2022 --> Oct 2021 | Trial primary completion date: Apr 2022 --> Oct 2021